Bapotulimab

Cat. No.:	HY-P99460
CAS No.:	2359413-58-2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects[1].
In Vitro	Bapotulimab blocks the immunosuppressive effects of ILDR2 on T-cell activation. Bapotulimab is mouse/human cross-reactive, as ILDR2 has a 98% sequence identity between the extracellular domains of human and murine orthologs[1]. Bapotulimab (BAY-1905254; 5, 25, 100, or 500 ng/mL) promotes T-cell activation in vitro and enhance antigen-specific T-cell proliferation[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Bapotulimab (BAY-1905254; 10 mg/kg; i.p.; on days 1 and 4) shows significantly increased antigen-specific T-cell proliferation and cytotoxicity[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8- to 12-week-old CD45.1-expressing C57BL/6 wild-type mice injected with OT-I transgenic T cells[1]
Dosage:	10 mg/kg
Administration:	i.p.; on days 1 and 4
Result:	Showed significantly increased antigen-specific T-cell proliferation and cytotoxicity.

REFERENCES

[1]. Julia Huetter, et al. Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA